Next Article in Journal
Impact of Analytical Treatment Interruption on Burden and Diversification of HIV Peripheral Reservoir: A Pilot Study
Next Article in Special Issue
Distinct Plasma Concentrations of Acyl-CoA-Binding Protein (ACBP) in HIV Progressors and Elite Controllers
Previous Article in Journal
Antibody Responsiveness to Influenza: What Drives It?
 
 
Article

Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study

1
Clinical Epidemiology Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy
2
Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy
3
Task Force Anti-COVID, AORN San Giuseppe Moscati, 83100 Avellino, Italy
4
ASST Santi Paolo e Carlo, Clinic of Infectious and Tropical Diseases, Department of Health Sciences, University of Milan, 20122 Milan, Italy
5
Icona Foundation, 20145 Milan, Italy
6
Department of Infectious Diseases, La Sapienza University, Polo Pontino, 04100 Latina, Italy
7
Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Policlinico Agostino Gemelli IRCCS, 00168 Rome, Italy
8
HIV/AIDS Clinical Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy
9
Division of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy
10
Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London WC1N 1EH, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Sonia Moretti
Viruses 2021, 13(7), 1402; https://doi.org/10.3390/v13071402
Received: 10 June 2021 / Revised: 13 July 2021 / Accepted: 13 July 2021 / Published: 19 July 2021
Objectives: HCV shows complex interactions with lipid metabolism. Our aim was to examine total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) changes in HIV/HCV coinfected patients, after achieving sustained virological response (SVR), according to different HCV genotypes and specific antiretroviral use. Methods: HIV/HCV coinfected patients, enrolled in the ICONA and HepaICONA cohorts, who achieved DAA-driven SVR were included. Paired t-tests were used to examine whether the pre- and post-SVR laboratory value variations were significantly different from zero. ANCOVA regression models were employed to estimate the causal effect of SVR and of PI/r use on lipid changes. The interaction between the effect of eradication and HCV genotype was formally tested. Results: six hundred and ninety-nine HIV/HCV coinfected patients were enrolled. After HCV eradication, a significant improvement in liver function occurred, with a significant decrease in AST, ALT, GGT, and total plasmatic bilirubin. TC and LDL-C significantly increased by 21.4 mg/dL and 22.4 mg/dL, respectively (p < 0.001), after SVR, whereas there was no evidence for a change in HDL-C (p = 0.45) and triglycerides (p = 0.49). Notably, the TC and LDL-C increase was higher for participants who were receiving darunavir/ritonavir, and the TC showed a more pronounced increase among HCV genotype 3 patients (interaction-p value = 0.002). Conclusions: complex and rapid changes in TC and LDL-C levels, modulated by HCV genotype and PI/r-based ART combinations, occurred in HIV/HCV coinfected patients after SVR. Further studies are needed to evaluate the clinical impact of these changes on the long-term risk of cardiovascular disease. View Full-Text
Keywords: HIV/HCV coinfected patients; HCV eradication; HCV genotype; lipid metabolism; antiretroviral treatment; darunavir/ritonavir HIV/HCV coinfected patients; HCV eradication; HCV genotype; lipid metabolism; antiretroviral treatment; darunavir/ritonavir
MDPI and ACS Style

Spaziante, M.; Taliani, G.; Marchetti, G.; Tavelli, A.; Lichtner, M.; Cingolani, A.; Cicalini, S.; Biliotti, E.; Girardi, E.; Antinori, A.; Puoti, M.; d’Arminio Monforte, A.; Cozzi-Lepri, A. Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study. Viruses 2021, 13, 1402. https://doi.org/10.3390/v13071402

AMA Style

Spaziante M, Taliani G, Marchetti G, Tavelli A, Lichtner M, Cingolani A, Cicalini S, Biliotti E, Girardi E, Antinori A, Puoti M, d’Arminio Monforte A, Cozzi-Lepri A. Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study. Viruses. 2021; 13(7):1402. https://doi.org/10.3390/v13071402

Chicago/Turabian Style

Spaziante, Martina, Gloria Taliani, Giulia Marchetti, Alessandro Tavelli, Miriam Lichtner, Antonella Cingolani, Stefania Cicalini, Elisa Biliotti, Enrico Girardi, Andrea Antinori, Massimo Puoti, Antonella d’Arminio Monforte, and Alessandro Cozzi-Lepri. 2021. "Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study" Viruses 13, no. 7: 1402. https://doi.org/10.3390/v13071402

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop